Stoke Therapeutics, Inc.

DB:0GT Stock Report

Market Cap: €564.1m

Stoke Therapeutics Management

Management criteria checks 3/4

Stoke Therapeutics' CEO is Ed Kaye, appointed in Oct 2017, has a tenure of 7.25 years. total yearly compensation is $3.53M, comprised of 17.7% salary and 82.3% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth €659.06K. The average tenure of the management team and the board of directors is 4 years and 6.3 years respectively.

Key information

Ed Kaye

Chief executive officer

US$3.5m

Total compensation

CEO salary percentage17.7%
CEO tenure7.3yrs
CEO ownership0.1%
Management average tenure4yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ed Kaye's remuneration changed compared to Stoke Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$105m

Jun 30 2024n/an/a

-US$104m

Mar 31 2024n/an/a

-US$109m

Dec 31 2023US$4mUS$626k

-US$105m

Sep 30 2023n/an/a

-US$103m

Jun 30 2023n/an/a

-US$105m

Mar 31 2023n/an/a

-US$99m

Dec 31 2022US$6mUS$596k

-US$101m

Sep 30 2022n/an/a

-US$100m

Jun 30 2022n/an/a

-US$96m

Mar 31 2022n/an/a

-US$94m

Dec 31 2021US$9mUS$568k

-US$86m

Sep 30 2021n/an/a

-US$76m

Jun 30 2021n/an/a

-US$67m

Mar 31 2021n/an/a

-US$58m

Dec 31 2020US$5mUS$549k

-US$52m

Sep 30 2020n/an/a

-US$48m

Jun 30 2020n/an/a

-US$43m

Mar 31 2020n/an/a

-US$38m

Dec 31 2019US$668kUS$477k

-US$32m

Sep 30 2019n/an/a

-US$26m

Jun 30 2019n/an/a

-US$21m

Mar 31 2019n/an/a

-US$16m

Dec 31 2018US$1mUS$464k

-US$13m

Compensation vs Market: Ed's total compensation ($USD3.53M) is above average for companies of similar size in the German market ($USD994.30K).

Compensation vs Earnings: Ed's compensation has been consistent with company performance over the past year.

CEO

Ed Kaye (75 yo)

7.3yrs

Tenure

US$3,533,210

Compensation

Dr. Edward M. Kaye, also known as Ed, M.D., Ph.D. has been Special Regulatory and Scientific Advisor of Sarepta Therapeutics, Inc. since June 28, 2017. He serves as Independent Director at Avidity Bioscien...

Leadership Team

NamePositionTenureCompensationOwnership
Edward Kaye
CEO & Director7.3yrsUS$3.53m0.12%
€ 659.1k
Adrian Krainer
Co-Founder & Independent Directorno dataUS$198.33k0.76%
€ 4.3m
Barry Ticho
Chief Medical Officer7.3yrsUS$1.65m0.084%
€ 476.5k
Isabel Aznarez
Co-Founderno datano datano data
Thomas Edward Leggett
Chief Financial Officerless than a yearno datano data
Eric Rojas
Head of Investor Relationsno datano datano data
Jonathan Allan
Corporate Secretary & General Counsel4yrsno data0.041%
€ 228.7k
Dawn Kalmar
Chief Communications Officer4yrsno datano data
Joan Wood
Chief Human Resources Officer5.3yrsno datano data
Shamim Ruff
Senior VP of Quality & Chief Regulatory Affairs Officer6.1yrsno datano data
Jason Hoitt
Chief Commercial Officerless than a yearno datano data
Eric Olson
Chief Business Officerless than a yearno datano data

4.0yrs

Average Tenure

52yo

Average Age

Experienced Management: 0GT's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Edward Kaye
CEO & Director7.3yrsUS$3.53m0.12%
€ 659.1k
Adrian Krainer
Co-Founder & Independent Director10.6yrsUS$198.33k0.76%
€ 4.3m
Seth Harrison
Independent Director9.5yrsUS$237.33k3.54%
€ 20.0m
Arthur Levin
Independent Director9.3yrsUS$198.33k0.034%
€ 191.4k
Ian Smith
Independent Director1.3yrsUS$394.03k0%
€ 0
Garry Menzel
Independent Director4.4yrsUS$199.33k0%
€ 0
Julie Smith
Independent Director4.6yrsUS$206.83k0%
€ 0
Jennifer Burstein
Independent Director5.6yrsUS$209.33k0%
€ 0
Arthur Tzianabos
Independent Chairman6.3yrsUS$211.83k0.060%
€ 338.0k

6.3yrs

Average Tenure

61yo

Average Age

Experienced Board: 0GT's board of directors are considered experienced (6.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 13:31
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Stoke Therapeutics, Inc. is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gregory HarrisonBofA Global Research
Thomas ShraderBTIG
Michelle GilsonCanaccord Genuity